De Motu Cordis Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series A
- (Upcoming)
- Investors
-
3
De Motu Cordis General Information
Description
Developer of a drug delivery platform designed for innovative products for the emergency treatment of life-threatening conditions. The company's platform utilizes the pulmonary pathway to deliver life-saving medication, treats anaphylaxis by delivering epinephrine through inhalation, and allows lung medications to be rapidly absorbed into the bloodstream, enabling healthcare providers to reduce long-term health costs for patients following cardiac arrest.
Contact Information
Website
www.demotucordis.coCorporate Office
- Unit 9, Level 1
- 121 Newmarket Road
- Windsor, Queensland 4032
- Australia
Corporate Office
- Unit 9, Level 1
- 121 Newmarket Road
- Windsor, Queensland 4032
- Australia
De Motu Cordis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | 01-Jun-2025 | Upcoming | Clinical Trials - Phase 1 | |||
| 5. Seed Round | Completed | Clinical Trials - Phase 1 | ||||
| 4. Grant | 06-Aug-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 03-Aug-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 30-Jun-2018 | $187K | $23.3K | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | 04-Oct-2013 | $23.3K | $23.3K | Completed | Clinical Trials - Phase 1 |
De Motu Cordis Patents
De Motu Cordis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023901616-A0 | Respiratory delivery device | Pending | 23-May-2023 | ||
| US-20230364362-A1 | Respiratory delivery device | Active | 23-May-2023 | ||
| US-12171934-B2 | Respiratory delivery device | Active | 23-May-2023 | ||
| AU-2022902269-A0 | Inhalable epinephrine formulation | Pending | 11-Aug-2022 | ||
| US-11684728-B2 | Automatic dispenser for respiratory delivery device | Active | 11-Aug-2022 | A61M15/0041 |
De Motu Cordis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
De Motu Cordis Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Texas Medical Center | Venture Capital | Minority | ||
| Advance Queensland | Government | |||
| Ignition Labs | Accelerator/Incubator | Minority |
De Motu Cordis FAQs
-
When was De Motu Cordis founded?
De Motu Cordis was founded in 2013.
-
Where is De Motu Cordis headquartered?
De Motu Cordis is headquartered in Windsor, Australia.
-
What is the size of De Motu Cordis?
De Motu Cordis has 13 total employees.
-
What industry is De Motu Cordis in?
De Motu Cordis’s primary industry is Pharmaceuticals.
-
Is De Motu Cordis a private or public company?
De Motu Cordis is a Private company.
-
What is De Motu Cordis’s current revenue?
The current revenue for De Motu Cordis is .
-
How much funding has De Motu Cordis raised over time?
De Motu Cordis has raised $20.9M.
-
Who are De Motu Cordis’s investors?
Texas Medical Center, Advance Queensland, and Ignition Labs have invested in De Motu Cordis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
